6838 Stock Overview
Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Formosa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$54.20 |
| 52 Week High | NT$66.90 |
| 52 Week Low | NT$49.00 |
| Beta | 1.03 |
| 1 Month Change | -2.52% |
| 3 Month Change | 9.72% |
| 1 Year Change | -10.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6838 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.1% | -4.9% | -2.6% |
| 1Y | -10.3% | 1.7% | 25.9% |
Return vs Industry: 6838 underperformed the TW Pharmaceuticals industry which returned 1.7% over the past year.
Return vs Market: 6838 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6838 volatility | |
|---|---|
| 6838 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6838 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6838's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Erick Co | www.formosapharma.com |
Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007, an aqueous-based ophthalmic nanosuspension that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002, a topical antibiotic for infectious eye diseases, such as blepharitis; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer, as well as lung fibrosis.
Formosa Pharmaceuticals, Inc. Fundamentals Summary
| 6838 fundamental statistics | |
|---|---|
| Market cap | NT$7.27b |
| Earnings (TTM) | -NT$321.96m |
| Revenue (TTM) | NT$31.17m |
233.2x
P/S Ratio-22.6x
P/E RatioIs 6838 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6838 income statement (TTM) | |
|---|---|
| Revenue | NT$31.17m |
| Cost of Revenue | NT$3.83m |
| Gross Profit | NT$27.35m |
| Other Expenses | NT$349.30m |
| Earnings | -NT$321.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.40 |
| Gross Margin | 87.73% |
| Net Profit Margin | -1,032.84% |
| Debt/Equity Ratio | 0% |
How did 6838 perform over the long term?
See historical performance and comparison